Daratumumab is an IgG1 kappa fully human moAb that targets CD38, which is highly expressed on malignant MM cells, but is also expressed on lymphoid and myeloid cells, hematopoietic progenitor cells, as well as non-hematopoietic tissues (18, 33). This evidence concerns the gene CD38 and Miyoshi myopathy.